London, UK, 28th November 2019 One Nucleus reveals the finalists of its annual BioNewsRound Award, recognising life science companies that have announced exciting developments for patients and the sector. The finalists will present at Genesis 2019 where the winner will be announced.
Companies were nominated for their most important news stories from the last year. These were assessed based on their impact on the organisation, whether they demonstrated an exciting development in the life sciences sector and whether they have the potential to significantly benefit…
AMSBIO reports on how it has worked with Singapore General Hospital (Singapore) to help them identify the best reagent to transfect their human embryonic stems cells.Historically the research group of Prof Tan Eng-King had used GeneIN, a transfection reagent specifically developed for stem cells which is now no longer available. Working with AMSBIO, Singapore General Hospital tested several reagents before electing to switch to GenePORTER® 2 to efficiently transfect their human embryonic stem cells. Senior researcher - Dr Christine Chan Hui Shan commented “Human embryonic stem cells…
Hertfordshire Local Enterprise Partnership is to invest £1.2m into Stevenage Bioscience Catalyst (SBC) to help grow a world-class cell and gene therapy cluster.
The £1.2m Local Growth Fund investment will provide much-needed temporary accommodation for growing cell and gene therapy companies, strengthening the UK’s sectorial advantage and Hertfordshire’s position within the Oxford-London-Cambridge golden research triangle.
SBC is a world-leading science park of global significance and home to the largest cluster of cell and gene therapy companies in Europe. Since its opening in 2012, it has…
Cambridge, UK, 19 November 2019: Chesterford Research Park and Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, announce that Microbiotica is relocating to the Park in a two-phase move that will be completed in June 2020.
Microbiotica’s continuing development and expansion, and the ability of Chesterford Research Park to flexibly accommodate both Microbiotica’s immediate and longer-term growth requirements led to the Park being chosen as the preferred location.
Under the first phase of the relocation, Microbiotica is taking two suites within Chesterford Research…
Arecor Limited (“the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, announces that its Chief Executive Officer, Dr Sarah Howell, will present at The sixth China Healthcare Summit, held from 18th to 20th November at the Jing An Shangri-La, Shanghai, China.
The Sixth China Healthcare Summit is the leading international forum to discuss how China is building the bridge to global healthcare. Dr Sarah Howell will address how UK Biopharmaceutical companies such as Arecor can collaborate with the growing innovative Chinese biotech ecosystem and…
Cambridge, UK, 14 November 2019: PredictImmune, developers of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases, is delighted to welcome James Clark as Chief Technology Officer.
Previously CEO of EnteroBiotix, specialists in the development of microbiome modulating therapeutics, James has extensive c-suite level experience in the development and commercialisation of diagnostic and therapeutic products. Prior to EnteroBiotix James’ roles included Vice President of Clinical Laboratory Operations at Inivata, Chief Technology…
Colorado, USA, November 13 2019: We are absolutely delighted to announce that Nilesh Dagia, COO, o2h discovery, has won the Go Beyond Award in the Individual category at the 2019 I2SL Annual Conference. The Go Beyond award goes to the individual that demonstrated a commitment to advancing both science and sustainability, and their efforts to contribute to the overall goal of more efficient laboratories across the world.
Nilesh won the award for leading the design and execution of energy-efficient and environmentally responsible labs for o2h discovery in India. The Go Beyond Awards is a unique…
Cambridge, UK, 11 November 2019 - TTP plc (TTP), a leading independent technology and product development company, today announced that its Desktop Biology™ service has enabled the fast-track development of a novel technology in partnership with DnaNudge Ltd, the developer of the world’s first DNA-based service to “nudge” consumers towards genetically optimal buying behaviour. The technology is designed to help consumers make healthier food and drink choices based on their unique genetic profile.
The DnaNudge experience provides the consumer with personalised product recommendations suited to…
Cambridge 11 November 2019: With the second wave of its ‘Accelerate@Babraham’ life sciences bio-incubator programme well underway, the Babraham Research Campus has confirmed additional financial and mentoring support for the initiative from Mundipharma. This sponsorship, alongside additional funding from AstraZeneca and LifeArc, further enhances the ability of the Babraham Research Campus to nurture new life science ventures and lead innovation in early science within the Cambridge cluster.
This year’s Accelerate@Babraham start-up competition awarded five ventures a cash prize of £10,000 and…
Cambridge, UK; November 8, 2019: Kymab, a clinical-stage biopharmaceutical company developing antibody-based therapeutics, will today present a poster detailing an expanding body of evidence for the activity of the company’s novel immunocytokine, KY1043. The poster will be presented at the Society of Immunotherapy for Cancer (SITC) 34th Annual Meeting being held today at the Gaylord National Hotel and Convention Center, National Harbor, Fort Washington, Maryland, United States.
KY1043 is a novel, fully-human, PD-L1-based, IL-2Ra (CD25)-directed immunocytokine that is designed to both…